• The political parties present at the Commission include, in their conclusions, the need to reinforce an active biosimilar policy that encourages their use, speeds up their authorization processes and establishes lines of joint collaboration between the Health Administration and the companies that develop biosimilars in Spain. .

The Spanish Association of Biosimilar Medicines, BioSim, values ​​very satisfactorily that the majority of the parliamentary groups present in the Commission for Social and Economic Reconstruction in the Congress of Deputies have included in their proposed conclusions the importance of medicines biosimilars to improve our health, and propose measures to promote their use within the National Health System (SNS).

BioSim sent its contributions and suggestions to the Health and Public Health Working Group set up within the framework of this Commission, which mainly included the establishment of strategies aimed at promoting the use of biosimilars to improve effectiveness and efficiency. in the SNS.

The general director of BioSim, Encarna Cruz, has indicated that "After the serious health crisis triggered by the COVID-19 pandemic, we are now faced with the need to reinforce the Health System to make it more agile and efficient, and for this it must be to be able to rearrange their resources and thus give a better response to the needs that the care and treatment of patients raises every day”. "In this sense, biosimilars are a key tool to improve the quality of care, to facilitate market price regulation, and to achieve a more efficient pharmaceutical prescription and a more sustainable health system," she adds.

Specifically, the conclusions drawn up by the main parliamentary groups include recommendations aimed at increasing the weight of biosimilars in the pharmaceutical provision of the SNS, such as streamlining the authorization processes for new biosimilar drugs or adopting measures that encourage the use effectiveness of these drugs.

"These measures show that the development of strategic actions in the field of biosimilars must constitute a basic component of the pharmaceutical policy of the SNS" has indicated the general director of BioSim. "The improvement in the measures aimed at increasing its use, as is already the case in other neighboring countries, constitutes a great opportunity to achieve these objectives," says Cruz.

Likewise, the implementation of collaboration mechanisms between the Health Administration and the companies that develop and produce biosimilars in Spain is also highly valued, as a measure that contributes to ensuring greater self-sufficiency of drugs that may be essential, ensuring minimum stocks in certain cases and reduce, with all this, the dependence of the SNS on third parties in a crisis situation such as the one experienced in recent months.

Encarna Cruz wanted to highlight the strategic role that the pharmaceutical industry in general and biosimilar companies in particular have played during this health crisis, which has allowed the maintenance of the availability and supply chain of these therapies, especially relevant for many chronic patients . "This effort leaves no doubt about the Industry's commitment to patients and the Health System, so we will always be willing to establish lines of collaboration with the Administration, in order to achieve a better SNS characterized by a greater capacity for resolution”, added Cruz.